IBDEI342 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,49685,2)
 ;;=^5003770^F02.80
 ;;^UTILITY(U,$J,358.3,49686,0)
 ;;=G31.01^^191^2477^26
 ;;^UTILITY(U,$J,358.3,49686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49686,1,3,0)
 ;;=3^Pick's Disease
 ;;^UTILITY(U,$J,358.3,49686,1,4,0)
 ;;=4^G31.01
 ;;^UTILITY(U,$J,358.3,49686,2)
 ;;=^329915
 ;;^UTILITY(U,$J,358.3,49687,0)
 ;;=G23.1^^191^2477^28
 ;;^UTILITY(U,$J,358.3,49687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49687,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,49687,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,49687,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,49688,0)
 ;;=E11.21^^191^2478^33
 ;;^UTILITY(U,$J,358.3,49688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49688,1,3,0)
 ;;=3^Type 2 DM w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,49688,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,49688,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,49689,0)
 ;;=E11.22^^191^2478^31
 ;;^UTILITY(U,$J,358.3,49689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49689,1,3,0)
 ;;=3^Type 2 DM w/ CKD
 ;;^UTILITY(U,$J,358.3,49689,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,49689,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,49690,0)
 ;;=E11.40^^191^2478^34
 ;;^UTILITY(U,$J,358.3,49690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49690,1,3,0)
 ;;=3^Type 2 DM w/ Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,49690,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,49690,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,49691,0)
 ;;=E11.65^^191^2478^32
 ;;^UTILITY(U,$J,358.3,49691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49691,1,3,0)
 ;;=3^Type 2 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,49691,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,49691,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,49692,0)
 ;;=E11.9^^191^2478^35
 ;;^UTILITY(U,$J,358.3,49692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49692,1,3,0)
 ;;=3^Type 2 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,49692,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,49692,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,49693,0)
 ;;=E03.9^^191^2478^26
 ;;^UTILITY(U,$J,358.3,49693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49693,1,3,0)
 ;;=3^Hypothyroidism
 ;;^UTILITY(U,$J,358.3,49693,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,49693,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,49694,0)
 ;;=N18.1^^191^2478^14
 ;;^UTILITY(U,$J,358.3,49694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49694,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 1
 ;;^UTILITY(U,$J,358.3,49694,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,49694,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,49695,0)
 ;;=N18.2^^191^2478^15
 ;;^UTILITY(U,$J,358.3,49695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49695,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 2
 ;;^UTILITY(U,$J,358.3,49695,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,49695,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,49696,0)
 ;;=N18.3^^191^2478^16
 ;;^UTILITY(U,$J,358.3,49696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49696,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 3
 ;;^UTILITY(U,$J,358.3,49696,1,4,0)
 ;;=4^N18.3
 ;;^UTILITY(U,$J,358.3,49696,2)
 ;;=^5015604
 ;;^UTILITY(U,$J,358.3,49697,0)
 ;;=N18.4^^191^2478^17
 ;;^UTILITY(U,$J,358.3,49697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49697,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 4
 ;;^UTILITY(U,$J,358.3,49697,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,49697,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,49698,0)
 ;;=N18.5^^191^2478^18
 ;;^UTILITY(U,$J,358.3,49698,1,0)
 ;;=^358.31IA^4^2
